The use of folic acid in dengue: has it any value?

Abstract

Folic acid is used in dengue patients. Our study aims to compare the duration of recovery of thrombocytopenia in patients with dengue infection who received folic acid and those who did not. We retrospectively reviewed the medical records of adult patients admitted over six years with a diagnosis of dengue. Of 2216 patients, 1464 fulfilled the inclusion criteria. Group A were those patients who received folic acid and group B were those who did not. A total of 1322 (90.3%) patients received folic acid. The mean time period required for platelets to double the nadir was 1.7 (±2.2) days in both groups A and B (P = 0.89). In conclusion, there is no significant difference in the recovery of thrombocytopenia in patients with dengue fever who received folic and those who did not receive folic acid.

Keywords

Dengue folic acid thrombocytopenia

Get full access to this article

View all access options for this article.

References

Jahan

. Dengue Fever (DF) in Pakistan. Asia Pac Fam Med 2011; 10: 1–1.

Shashidhara

Murthy

KAS

Gowdappa

et al.

Effect of high dose of steroid on platelet count in acute stage of dengue fever with thrombocytopenia. J Clin Diagn Res 2013; 7: 1397–1400.

Sanchez-Valdez

Delgado-Aradillas

Torres-Martinez

et al.

Clinical response in patients with dengue fever to oral calcium plus vitamin D administration: study of 5 cases. Proc West Pharmacol Soc 2009; 52: 14–17.

Ahmad

Fazal

Ayaz

et al.

Dengue fever treatment with Carica papaya leaves extracts. Asian Pac J Trop Biomed 2011; 1: 330–333.

Tricou

Minh

Van

et al.

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4: e785–e785.

Dimaano

Saito

Honda

et al.

Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007; 77: 1135–1138.

Jayasinghe

Thalagala

Wattegama

et al.

Dengue fever with diffuse cerebral hemorrhages, subdural hematoma and cranial diabetes insipidus. BMC Res Notes 2016; 9: 265–265.

Ghazala

Anuradha

Shivamurthy

. Pattern of management and outcome of dengue fever in pediatric in-patients in a tertiary care hospital: a prospective observational study. International Journal of Basic & Clinical Pharmacology 2014; 3: 534–538.

Fischer

Smith

Shum

et al.

Flaviviruses are sensitive to inhibition of thymidine synthesis pathways. J Virol 2013; 87: 9411–9419.

10.

World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: WHO, 2009. Available at: http://www.who.int/rpc/guidelines/9789241547871/en/.

11.

Atrasheuskaya

Petzelbauer

Fredeking

et al.

Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 2003; 35: 33–42.

12.

Rathore

Paradkar

Watanabe

et al.

Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011; 92: 453–460.

13.

Chang

Schul

Butters

et al.

Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res 2010; 89: 26–34.